Should You Buy Passage Bio, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Passage Bio, Inc. (PASG) presents a moderate quality profile with a QOC score of 4.3/10. Trading at $4.77, separating genuine undervalued opportunities from value traps is essential, as detailed by our model data.
The short answer: 1 of 2 CirclFi valuation models project upside for Passage Bio, Inc. (PASG) at $4.77 — the models are evenly split, with a Quality Score of 4.3/10 and Value-Trap risk of 34/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Passage Bio, Inc. (PASG) in 2026?
What Is the Bull Case vs the Bear Case for Passage Bio, Inc. (PASG)?
| Bull case — $15.94 target (+234.3%) | Bear case — $4.40 target (-7.8%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $4.77 and the median fair value of $10.17 implies +113.2% upside potential. | According to the CirclFi Quality of Company (QOC) framework, Passage Bio, Inc.'s rating of 4.3/10 indicates below-average quality, raising questions about sustainable earnings levels. |
| According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model targets a fair value of $15.94 (+234.3%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +242.1% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: platform technology validation could provide meaningful support for Passage Bio, Inc.'s revenue and margin trajectory in the Biotechnology space. | Industry headwind: dilutive capital raises represents a meaningful risk for Passage Bio, Inc. and its Biotechnology peers. |
How Does PASG Compare to Its Biotechnology Peers?
Valuation data pages: APVO · BBLG · SMNR · ENVB · CLDI · INDP · TECH · INBX · ALGS · EXEL · INCY
Which Other Stocks Score Like PASG on Quality?
Closest companies to PASG’s Quality of Company score of 4.3/10, across all industries.
- PMI — Picard Medical, Inc. (QOC 4.3) · analysis
- NVNO — enVVeno Medical Corporation (QOC 4.3) · analysis
- EDBL — Edible Garden AG Incorporated (QOC 4.3) · analysis
- RGNT — Regentis Biomaterials Ltd. (QOC 4.3) · analysis
- SATT — Sativus Tech Corp. (QOC 4.3) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does PASG Appear In?
So Is Passage Bio, Inc. (PASG) Worth Buying in 2026?
Our models don't have a clear verdict on Passage Bio, Inc.. At $4.77 vs. $10.17 median fair value, the median upside of +113.2% masks significant model disagreement (+242.1% spread). With quality at 4.3/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. Passage Bio, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About PASG Stock?
Should I buy PASG stock right now?
Based on CirclFi's multi-model analysis, 1 of 2 models see upside for PASG at $4.77. The models are divided, which means the investment case depends heavily on your assumptions about Passage Bio, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Passage Bio, Inc.?
Key risks include: a below-average Quality Score of 4.3/10, indicating fundamental weakness; limited model coverage (2/13 active), reducing analytical confidence; wide model disagreement (263% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does PASG compare to its competitors?
Among Biotechnology peers, PASG holds a Quality Score of 4.3/10. Comparable companies include APVO (QOC 4.3), BBLG (QOC 4.3), SMNR (QOC 4.3). The relative ranking helps investors identify whether PASG offers better fundamental quality than alternatives in the same sector.
Is PASG a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PASG's Quality Score of 4.3/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy PASG at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $4.40 to $15.94. At $4.77, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for PASG.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad